A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

NCT07579936 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG: SAL056 56.5μg
DRUG: Intervention Group 1
DRUG: Intervention Group 2
DRUG: Intervention Group 3

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Collaborators

[object Object]